154 related articles for article (PubMed ID: 2502523)
1. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
Kuroki Y; Shimoyama M; Inaba S; Hirose M
Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523
[TBL] [Abstract][Full Text] [Related]
2. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
[TBL] [Abstract][Full Text] [Related]
3. Opposite effects of recombinant interferon-alpha A and deoxycoformycin on adenosine deaminase activity in the Daudi B lymphoblastoid cell line.
Faltynek CR
Blood; 1988 Jan; 71(1):59-64. PubMed ID: 3257147
[TBL] [Abstract][Full Text] [Related]
4. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
5. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.
Plunkett W; Benjamin RS; Keating MJ; Freireich EJ
Cancer Res; 1982 May; 42(5):2092-6. PubMed ID: 6175407
[TBL] [Abstract][Full Text] [Related]
6. Therapy with 9-beta-D-arabinofuranosyladenine (ARA-A) and 2'-deoxycoformycin increases the ARA-A content of ocular tissues.
O'Brien WJ
Curr Eye Res; 1986 Aug; 5(8):595-9. PubMed ID: 3489583
[TBL] [Abstract][Full Text] [Related]
7. Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A).
Yu AL; Mendelsohn J; Matsumoto SS
Adv Exp Med Biol; 1986; 195 Pt A():491-6. PubMed ID: 3487920
[No Abstract] [Full Text] [Related]
8. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
Holland MJ
Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
Cass CE; Au-Yeung TH
Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the anti-herpesvirus drug combinations: virazole plus arabinofuranosylhypoxanthine and virazole plus arabinofuranosyladenine.
Allen LB; Vanderslice LK; Fingal CM; McCright FH; Harris EF; Cook PD
Antiviral Res; 1982 Sep; 2(4):203-16. PubMed ID: 6293375
[TBL] [Abstract][Full Text] [Related]
11. Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin.
Schwartz CL; Minniti CP; Harwood P; Na S; Banquerigo ML; Strauss LC; Kurtzberg J; Smith SD; Civin CI
J Clin Oncol; 1987 Dec; 5(12):1900-11. PubMed ID: 3500279
[TBL] [Abstract][Full Text] [Related]
12. Biochemical mechanisms of deoxycoformycin toxicity in chronic leukemias.
Ganeshaguru K; Ho AD; Piga A; Catovsky D; Hoffbrand AV
Leuk Res; 1987; 11(10):941-5. PubMed ID: 3500370
[TBL] [Abstract][Full Text] [Related]
13. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response.
Ho AD; Ganeshaguru K; Knauf W; Dietz G; Trede I; Hoffbrand AV; Hunstein W
Leuk Res; 1989; 13(4):269-78. PubMed ID: 2785618
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
Cass CE; Tan TH; Selner M
Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity of leukemic cells to growth inhibition by deoxyadenosine and deoxycoformycin.
Tanaka M; Kimura K
Tohoku J Exp Med; 1985 Dec; 147(4):331-41. PubMed ID: 3879563
[TBL] [Abstract][Full Text] [Related]
16. [Problems of antineoplastic effects by PLDR (potential lethal damage repair) inhibitor--pharmacokinetics].
Sougawa M; Akagi K; Yoshii G; Tanaka Y
Gan No Rinsho; 1984 Nov; 30(14):1787-92. PubMed ID: 6334757
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin.
Major PP; Agarwal RP; Kufe DW
Cancer Chemother Pharmacol; 1983; 10(2):125-8. PubMed ID: 6600984
[No Abstract] [Full Text] [Related]
18. dATP-mediated inhibition of DNA ligase by 2'-deoxycoformycin in T and B cell leukemia.
Lamballe F; Le Prise PY; Le Gall E; David JC
Leukemia; 1989 Feb; 3(2):97-103. PubMed ID: 2783473
[TBL] [Abstract][Full Text] [Related]
19. 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells.
Ruers TJ; Buurman WA; van der Linden CJ
J Immunol; 1987 Jan; 138(1):116-22. PubMed ID: 3097141
[TBL] [Abstract][Full Text] [Related]
20. Morphologic changes and immunohistochemical localization of adenosine deaminase in tissues of rats given injections of 2'-deoxycoformycin.
Checkik BE; Perets A; SenGupta S; Fernandes B
J Natl Cancer Inst; 1983 Nov; 71(5):999-1010. PubMed ID: 6358608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
